Quarterly report pursuant to Section 13 or 15(d)

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.23.3
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Jan. 17, 2019
Allowance for doubtful accounts $ 0   $ 0   $ 0  
Impairment of assets 0   0      
Impairment of intellectual property 0 $ 0 47,980 $ 0    
Advertising costs 25,846 106,073 88,633 295,119    
Impairment loss     47,980      
Grant funding during the first year           $ 2,842,430
Grant funding during the second year           2,831,838
Grant funding during the third year           3,453,367
Grant additional funding during the third year           $ 99,431
Grant receivables 4,991   4,991   122,652  
Deferred income     0   0  
Grant income 300,985 390,857 790,140 1,250,231    
F & A indirect costs 0   0   $ 253,208  
Grant funding indirect cost     516,218      
Allocation of remaining F & A indirect cost 9,671   9,671      
Research and development expenses $ 286,962 $ 342,553 $ 762,768 $ 923,354    
Ownership percentage     50.00%      
Royalty obligations description     The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued      
Description of Non-Controlling Interest     Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest      
Royalty obligations, net     $ 7,171,200      
Minimum [Member]            
Property plant and equipment estimated useful lives     5 years      
Maximum [Member]            
Property plant and equipment estimated useful lives     15 years